Icon

Lexicon’s LX4211 trial shows positive results

Tuesday, September 13, 2011 11:30 AM

Lexicon Pharmaceuticals reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

More... »

Icon CEO Peter Gray to step down after nine years; CFO Ciaran Murray takes the helm as of Oct. 1

Monday, September 12, 2011 08:02 AM

Peter Gray, CEO of Icon since 2002, will step down as of Oct. 1. The announcement, which came last week, surprised many in the industry.  Icon’s board has appointed Ciaran Murray, who has been Icon’s CFO for the last six years, to succeed Gray as CEO.

More... »

WCCT names Affrime senior VP

Friday, September 9, 2011 01:21 PM

West Coast Clinical Trials has named Melton Affrime senior vice president, research and development, to further develop their growing clinical research capabilities.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

Choo joins Menicon

Tuesday, August 23, 2011 12:06 PM

Menicon has named Dr. Jennifer Choo manager of specialty lens clinical affairs for Menicon Holdings B.V. Choo will oversee the company's Rose K business while also handling professional and clinical affairs for the company's growing specialty lens portfolio.

More... »

Lexicon’s phase II LX1032 trial shows positive results

Tuesday, August 16, 2011 02:03 PM

Lexicon Pharmaceuticals has reported positive, top-line proof-of-concept data from its recently completed phase II study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Symptoms of carcinoid syndrome have been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is designed to reduce serotonin production.

More... »

Omthera names Lloyd VP regulatory affairs

Monday, August 1, 2011 12:32 PM

Omthera Pharmaceuticals reports that Ramona M. Lloyd has joined the company as vice president regulatory affairs, effective immediately.  In this newly created position, Dr. Lloyd will be responsible for the management of all regulatory activities, including regulatory strategy and interactions with the FDA.

More... »

Lexicon successfully completes phase I LX1033 trial

Friday, July 29, 2011 11:16 AM

Lexicon Pharmaceuticals has successfully completed a phase I clinical trial of LX1033, an orally-delivered small-molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).  Lexicon plans to move LX1033 forward into a phase II study in patients with IBS-d.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

ICON acquires Firecrest Clinical to enhance site performance

Thursday, July 14, 2011 01:03 PM

Dublin, Ireland-based global CRO Icon has agreed to acquire Firecrest Clinical, a provider of technology solutions that boost investigator site performance and study management.

More... »